Geneticure
Business Services · Minnesota, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4 3rd St SW Ste 305B, Rochester, Minneso...Phone Number
(800) 362-8109Website
www.geneticure.comRevenue
<$5 MillionIndustry
About Geneticure
Geneticure Org Chart
Is Geneticure your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Geneticure recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Geneticure is spiking on competitors!
Geneticure, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Geneticure
Check if Geneticure has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Geneticure has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Geneticure had a recent Job posting/layoffs
Product Launch: Get notified when Geneticure launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Geneticure
Compare insights from companies similar to Geneticure, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Geneticure is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Geneticure is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Geneticure.
Geneticure financials insights
Gather financial insights about Geneticure, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Private Equity
$665K
Geneticure Tech Stack
A closer look at the technologies used by Geneticure
Geneticure News & Media
Geneticure Presents Data Successfully Using Genetics to Identify Responders to Renal Denervation
Patients with a high responder score had a ~14mmHg drop in blood pressure and those with a low score had no change in blood pressure. (PRWeb November 21, 2022) Read the full story at https://www.prweb.com/releases/2022/11/prweb19032833.htmGeneticure Announces Technology to Drive an Estimated 250% Increase in Renal Denervation Adoption Using Genetic Screening to Rule Out Non-responders
Studies demonstrate that approx. 1 in 3 patients with renal denervation do not have a meaningful drop in Blood Pressure (5mmHg according to the American Heart Association) and ~20% have an increase in Blood Pressure. (PRWeb February 21, 2022) Read the full story at https://www.prweb.com/releases/geneticure_announces_technology_to_drive_an_estimated_250_increase_in_renal_denervation_adoption_using_genetic_screening_to_rule_out_non_responders/prweb18509885.htmGeneticure Awarded Patent for Precision Medicine Blood Pressure Treatment
Previously published Geneticure research has demonstrated significantly lower blood pressure and lower cost of care when patients match Geneticure’s recommended medications. (PRWeb September 17, 2019) Read the full story at https://www.prweb.com/releases/geneticure_awarded_patent_for_precision_medicine_blood_pressure_treatment/prweb16575176.htm
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Geneticure
Geneticure specializes in personalized medicine by offering a patented DNA test that recommends tailored treatment plans for hypertension. Their innovative approach utilizes a cheek swab to analyze genetic factors, helping healthcare providers prescribe the most effective blood pressure medications from the outset. The company aims to reduce trial-... Read More